Q1 2026 Earnings Estimate for Elevance Health, Inc. (NYSE:ELV) Issued By Zacks Research

Elevance Health, Inc. (NYSE:ELV) – Analysts at Zacks Research raised their Q1 2026 earnings per share (EPS) estimates for shares of Elevance Health in a report released on Wednesday, April 24th. Zacks Research analyst K. Dey now anticipates that the company will post earnings per share of $13.50 for the quarter, up from their previous forecast of $12.58. The consensus estimate for Elevance Health’s current full-year earnings is $37.24 per share.

Several other analysts have also recently weighed in on ELV. Mizuho raised their price target on Elevance Health from $575.00 to $585.00 and gave the company a “buy” rating in a report on Wednesday. Barclays raised their price objective on Elevance Health from $584.00 to $621.00 and gave the company an “overweight” rating in a report on Friday, April 19th. Truist Financial reissued a “buy” rating and set a $600.00 price objective (up from $580.00) on shares of Elevance Health in a report on Friday, April 19th. Cantor Fitzgerald reissued an “overweight” rating and set a $580.00 price objective on shares of Elevance Health in a report on Wednesday, April 10th. Finally, Jefferies Financial Group raised their price objective on Elevance Health from $602.00 to $604.00 and gave the company a “buy” rating in a report on Friday, April 19th. One equities research analyst has rated the stock with a hold rating and thirteen have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $587.42.

Elevance Health Stock Performance

NYSE:ELV opened at $537.26 on Friday. The business’s 50-day moving average price is $511.89 and its two-hundred day moving average price is $486.62. Elevance Health has a twelve month low of $412.00 and a twelve month high of $542.07. The stock has a market cap of $124.87 billion, a P/E ratio of 20.30, a PEG ratio of 1.19 and a beta of 0.78. The company has a quick ratio of 1.37, a current ratio of 1.37 and a debt-to-equity ratio of 0.54.

Elevance Health (NYSE:ELV) last released its quarterly earnings results on Thursday, April 18th. The company reported $10.64 earnings per share for the quarter, beating the consensus estimate of $10.54 by $0.10. Elevance Health had a return on equity of 20.62% and a net margin of 3.64%. The firm had revenue of $42.27 billion for the quarter, compared to analysts’ expectations of $42.49 billion. During the same quarter last year, the firm posted $9.46 EPS. The company’s revenue was up .9% compared to the same quarter last year.

Institutional Investors Weigh In On Elevance Health

A number of large investors have recently made changes to their positions in ELV. Norges Bank bought a new stake in shares of Elevance Health in the 4th quarter worth approximately $1,347,434,000. Massachusetts Financial Services Co. MA bought a new stake in shares of Elevance Health during the fourth quarter valued at approximately $467,141,000. Canoe Financial LP boosted its position in shares of Elevance Health by 158.1% during the fourth quarter. Canoe Financial LP now owns 844,122 shares of the company’s stock valued at $398,054,000 after purchasing an additional 517,116 shares in the last quarter. Morningstar Investment Services LLC bought a new stake in shares of Elevance Health during the fourth quarter valued at approximately $239,244,000. Finally, Focused Investors Fund L P bought a new stake in shares of Elevance Health during the first quarter valued at approximately $249,884,000. 89.24% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Elevance Health news, Director Ramiro G. Peru sold 753 shares of Elevance Health stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $500.00, for a total value of $376,500.00. Following the transaction, the director now directly owns 9,109 shares of the company’s stock, valued at approximately $4,554,500. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, Director Ramiro G. Peru sold 753 shares of Elevance Health stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $500.00, for a total value of $376,500.00. Following the sale, the director now directly owns 9,109 shares in the company, valued at approximately $4,554,500. The sale was disclosed in a filing with the SEC, which is available through this link. Also, EVP Felicia F. Norwood sold 14,111 shares of Elevance Health stock in a transaction that occurred on Tuesday, April 23rd. The stock was sold at an average price of $533.74, for a total value of $7,531,605.14. Following the completion of the sale, the executive vice president now owns 31,460 shares in the company, valued at $16,791,460.40. The disclosure for this sale can be found here. Insiders own 0.35% of the company’s stock.

Elevance Health Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 25th. Shareholders of record on Monday, June 10th will be paid a $1.63 dividend. The ex-dividend date of this dividend is Monday, June 10th. This represents a $6.52 dividend on an annualized basis and a yield of 1.21%. Elevance Health’s dividend payout ratio (DPR) is currently 24.64%.

Elevance Health Company Profile

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.